Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 11 to 20 of 2440 total matches.
Omalizumab (Xolair) for Food Allergy
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
, and chronic urticaria,1,2 has now
also been approved for use in conjunction with food
allergen avoidance ...
Omalizumab (Xolair – Genentech), a recombinant
anti-IgE monoclonal antibody FDA-approved for
treatment of allergic asthma, chronic rhinosinusitis
with nasal polyps, and chronic urticaria, has now
also been approved for use in conjunction with food
allergen avoidance to reduce IgE-mediated food
allergic reactions caused by accidental exposure in
patients ≥1 year old. Omalizumab is the first drug to
be approved in the US to reduce allergic reactions to
more than one food. Palforzia, an oral peanut allergen
powder, was approved in 2020 to mitigate allergic
reactions caused by...
Med Lett Drugs Ther. 2024 Apr 1;66(1699):54-6 doi:10.58347/tml.2024.1699b | Show Introduction Hide Introduction
Addendum: Bupropion Safety in Pregnancy
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
Addendum: Bupropion Safety in Pregnancy
Volume 66 (Issue 1699) April 1, 2024
Our December 11 ...
Our December 11, 2023 article on Drugs for Depression included a single sentence on the safety of bupropion use during
pregnancy: "The safety of bupropion during pregnancy has
not been established; data from a bupropion pregnancy registry
suggested a possible increase in cardiac malformations."
A reader asked us to provide more information.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):56 doi:10.58347/tml.2024.1699c | Show Introduction Hide Introduction
Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
hours. They do not decrease airway inflammation.1
Treatment guidelines now recommend that most ...
The FDA has approved Airsupra (AstraZeneca), a
metered-dose inhaler containing the short-acting
beta2-agonist (SABA) albuterol and the inhaled
corticosteroid (ICS) budesonide, for use as needed for
treatment or prevention of bronchoconstriction and to
reduce the risk of exacerbations in patients ≥18 years
old with asthma. Airsupra is the first combination of
a SABA and an ICS to become available in the US. It is
not approved for use as maintenance therapy.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):41-3 doi:10.58347/tml.2024.1698a | Show Introduction Hide Introduction
Penbraya: A Pentavalent Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
, and Y (MenACWY; Menveo, MenQuadfi)1 and
two meningococcal serogroup B vaccines (MenB;
Bexsero ...
The FDA has licensed Penbraya (Pfizer), a pentavalent
polysaccharide conjugate meningococcal
vaccine, for prevention of invasive meningococcal
disease caused by Neisseria meningitidis
serogroups A, B, C, W, or Y (MenABCWY) in persons
10-25 years old. Penbraya is the only meningococcal
vaccine that contains all five of these serogroups.
Two quadrivalent polysaccharide conjugate
meningococcal vaccines containing serogroups A,
C, W, and Y (MenACWY; Menveo, MenQuadfi) and
two meningococcal serogroup B vaccines (MenB;
Bexsero, Trumenba) are available in the US (see
Table...
Med Lett Drugs Ther. 2024 Mar 18;66(1698):43-5 doi:10.58347/tml.2024.1698b | Show Introduction Hide Introduction
Mirikizumab (Omvoh) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
with a biologic drug, but the risk of
lymphoma is a concern.1-5
PHARMACOLOGY — IL-23 is a proinflammatory ...
The FDA has approved the interleukin (IL)-23
antagonist mirikizumab-mrkz (Omvoh – Lilly) for
treatment of moderately to severely active ulcerative
colitis (UC) in adults. Mirikizumab is the first selective
IL-23 antagonist to be approved for this indication.
Ustekinumab (Stelara), an IL-12/23 antagonist, was
approved for treatment of UC in 2019. The IL-23
antagonist risankizumab (Skyrizi) is approved for
treatment of Crohn's disease.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):46-7 doi:10.58347/tml.2024.1698c | Show Introduction Hide Introduction
In Brief: A New OTC Naloxone Nasal Spray (RiVive)
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
) product for emergency
treatment of opioid overdose.1 Two 4-mg naloxone
nasal spray formulations, Narcan ...
The FDA has approved RiVive (Harm Reduction
Therapeutics), a 3-mg naloxone nasal spray, as
an over-the-counter (OTC) product for emergency
treatment of opioid overdose. Two 4-mg naloxone
nasal spray formulations, Narcan and one of its
generics, were approved for OTC sale in 2023.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):47-8 doi:10.58347/tml.2024.1698d | Show Introduction Hide Introduction
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
is the most effective treatment for GSM.1 When OTC
nonhormonal products are ineffective, low-dose
vaginal ...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 doi:10.58347/tml.2024.1697a | Show Introduction Hide Introduction
Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
. It was
previously approved as Ibsrela to treat irritable bowel
syndrome with constipation (IBS-C).1
STANDARD ...
The FDA has approved the sodium/hydrogen
exchanger 3 (NHE3) inhibitor tenapanor (Xphozah –
Ardelyx) to reduce serum phosphorus in adults with
chronic kidney disease (CKD) on dialysis as add-on
therapy when phosphate binders are ineffective or
as monotherapy when phosphate binders cannot be
tolerated. Tenapanor is the first NHE3 inhibitor to be
approved in the US for hyperphosphatemia. It was
previously approved as Ibsrela to treat irritable bowel
syndrome with constipation (IBS-C).
Med Lett Drugs Ther. 2024 Mar 4;66(1697):38-9 doi:10.58347/tml.2024.1697b | Show Introduction Hide Introduction
In Brief: Severe Hypocalcemia with Denosumab (Prolia) in Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
4, 2024
The FDA is requiring a boxed warning in the label
of denosumab (Prolia – Amgen)1 ...
The FDA is requiring a boxed warning in the label
of denosumab (Prolia – Amgen), a monoclonal
antibody that inhibits osteoclasts, about an
increased risk of severe hypocalcemia in patients
with advanced chronic kidney disease (CKD;
eGFR <30 mL/min/1.73 m2), particularly those on
dialysis. FDA-approved indications for Prolia are
listed in Table 1.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):40 doi:10.58347/tml.2024.1697c | Show Introduction Hide Introduction
Capivasertib (Truqap) for Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
) inhibitor such as
palbociclib (Ibrance).1,2
MECHANISM OF ACTION ― The PI3K/AKT/PTEN
signaling pathway ...
The oral kinase inhibitor capivasertib (Truqap –
AstraZeneca), a first-in-class AKT inhibitor, has
been approved by the FDA for use in combination
with the selective estrogen receptor degrader (SERD)
fulvestrant (Faslodex, and generics) for treatment of
hormone receptor (HR)-positive, human epidermal
growth factor receptor 2 (HER2)-negative, locally
advanced or metastatic breast cancer in adults with
one or more PIK3CA/AKT1/PTEN-alterations who had
disease progression on at least one endocrine-based
regimen for metastatic disease or recurrence on or
within 12 months of completing...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e32-3 doi:10.58347/tml.2024.1696e | Show Introduction Hide Introduction